Login / Register The Most Trusted Name in Medical Education

Hematology

Improve your hematology practice by taking one of Elsevier's complimentary continuing medical education courses.

910733 116 x 140

Integrating Biosimilars into Supportive Care: Insights for Informed Decisions

Format: Webcast

Biosimilars, which have been available in Europe for more than 10 years, are increasingly gaining regulatory approval in the United States. These agents have the potential to contain rapidly increasing health care costs and simultaneously enable greater patient access. The cornerstone of broad acceptance of biosimilars is increased education of all involved parties regarding regulatory standards for biosimilar approval, preclinical and clinical data requirements, interchangeability, and extrapolation of indications.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
ASCO ESMO 116x141

ASCO & ESMO 2017 Highlights: Incorporating Immuno-oncology Agents into Solid and Liquid Tumor Treatment Paradigms

Format: Webcast

 The goal of this initiative is to help medical oncology and hematology-oncology physicians and advanced practitioners in community and academic settings to integrate checkpoint inhibitors into cancer treatment regimens and understand their unique safety and response profiles.

Take Courses »

 

Credits: Earn up to 2.0 AMA PRA Category 1 Credit(s)™
910703 116 x 140

Current and Future Therapies for Cytomegalovirus (CMV) Infection

Format: Webcast

Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT, as well as with increased risk of secondary bacterial and fungal infections. Antiviral prophylaxis, more commonly used after SOT, is effective against direct and indirect effects of CMV infection, but may lead to overtreatment. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Several antiviral agents are currently available for CMV management; however, their use may be associated with myelosuppression and nephrotoxicity. Novel antiviral therapies with different mechanisms of action are in late-stage development and hold the promise of reducing CMV-related morbidity and mortality.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit(s)™
Elsevier EHA 2017 Web 116x140 v3

EMERGING TARGETED THERAPIES IN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

Format: Medical Meeting Reporter

This webcast on relapsed/refractory acute lymphoblastic leukemia (R/R ALL) is based on a roundtable discussion by three experts, who provide an overview of challenges in the treatment of R/R ALL and summarize and discuss the latest data presented during the European Hematology Association (EHA) Annual Congress 2017, held on June 22–25 in Madrid, Spain. Progressing clinical trial outcomes of targeted therapies for R/R ALL, such as the anti-CD22 immunoconjugate inotuzumab ozogamicin, the anti-CD19 bi-specific T-cell engager (BiTE) blinatumomab, and CAR-T cell therapy will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with R/R ALL.

 

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
ASCO ESMO 116x140

Incorporating Immuno-oncology Agents into Solid and Liquid Tumor Treatment Paradigms: Highlights from ASCO 2017 – Expert Discussion

Format: Webcast

Immunotherapy is now an established treatment approach for patients with cancer across oncology. Immunotherapy agents are a newer type of anticancer drug, and the drugs in the largest class, checkpoint inhibitors, block the checkpoint pathways that cancer cells use to shut down the patient’s immune system. Checkpoint inhibitors are associated with more durable clinical responses compared to both small molecule targeted therapy and conventional chemotherapy (CT). Because checkpoint inhibitors have unique mechanisms of action, they also produce immune-related adverse events and response patterns that are markedly distinct from targeted agents or conventional CT. The 5 currently available immunotherapy agents have 18 indications across multiple cancer types. Checkpoint inhibitors demonstrate the potential to change current cancer treatment paradigms.                        

In this interactive CE activity, a leading medical oncologist discusses highlights of several key presentations from the 2017 American Society of Clinical Oncology (ASCO) Annual  Meeting on the use of checkpoint inhibitors in several cancer types. Topics include questions on appropriate clinical setting for immunotherapy (eg, refractory cancer), dose, combination therapy, treatment beyond progression, and side-effect profile for patients.

Take Course »

Credits: 0.5 AMA PRA Category 1 Credit™